UNICYCIVE THERAPEUTICS INC (UNCY) Fundamental Analysis & Valuation

NASDAQ:UNCY • US90466Y2028

Current stock price

7.67 USD
+0.01 (+0.13%)
At close:
7.5597 USD
-0.11 (-1.44%)
After Hours:

This UNCY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. UNCY Profitability Analysis

1.1 Basic Checks

  • UNCY had negative earnings in the past year.
  • UNCY had a negative operating cash flow in the past year.
  • UNCY had negative earnings in each of the past 5 years.
  • UNCY had a negative operating cash flow in each of the past 5 years.
UNCY Yearly Net Income VS EBIT VS OCF VS FCFUNCY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of UNCY (-105.21%) is worse than 77.71% of its industry peers.
  • UNCY's Return On Equity of -192.09% is on the low side compared to the rest of the industry. UNCY is outperformed by 69.57% of its industry peers.
Industry RankSector Rank
ROA -105.21%
ROE -192.09%
ROIC N/A
ROA(3y)-327.07%
ROA(5y)-432.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
UNCY Yearly ROA, ROE, ROICUNCY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 -5K -10K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for UNCY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UNCY Yearly Profit, Operating, Gross MarginsUNCY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. UNCY Health Analysis

2.1 Basic Checks

  • UNCY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, UNCY has more shares outstanding
  • The number of shares outstanding for UNCY has been increased compared to 5 years ago.
  • There is no outstanding debt for UNCY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
UNCY Yearly Shares OutstandingUNCY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
UNCY Yearly Total Debt VS Total AssetsUNCY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

  • UNCY has an Altman-Z score of 0.85. This is a bad value and indicates that UNCY is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.85, UNCY is in the better half of the industry, outperforming 60.27% of the companies in the same industry.
  • There is no outstanding debt for UNCY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.85
ROIC/WACCN/A
WACC9.49%
UNCY Yearly LT Debt VS Equity VS FCFUNCY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M

2.3 Liquidity

  • UNCY has a Current Ratio of 2.18. This indicates that UNCY is financially healthy and has no problem in meeting its short term obligations.
  • UNCY has a Current ratio of 2.18. This is in the lower half of the industry: UNCY underperforms 75.97% of its industry peers.
  • A Quick Ratio of 2.18 indicates that UNCY has no problem at all paying its short term obligations.
  • UNCY's Quick ratio of 2.18 is on the low side compared to the rest of the industry. UNCY is outperformed by 73.84% of its industry peers.
Industry RankSector Rank
Current Ratio 2.18
Quick Ratio 2.18
UNCY Yearly Current Assets VS Current LiabilitesUNCY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. UNCY Growth Analysis

3.1 Past

  • UNCY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.73%, which is quite impressive.
EPS 1Y (TTM)79.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, UNCY will show a very strong growth in Earnings Per Share. The EPS will grow by 40.55% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y37.81%
EPS Next 2Y198.81%
EPS Next 3Y81.16%
EPS Next 5Y40.55%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
UNCY Yearly Revenue VS EstimatesUNCY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
UNCY Yearly EPS VS EstimatesUNCY Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. UNCY Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for UNCY. In the last year negative earnings were reported.
  • Also next year UNCY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UNCY Price Earnings VS Forward Price EarningsUNCY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UNCY Per share dataUNCY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

  • UNCY's earnings are expected to grow with 81.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y198.81%
EPS Next 3Y81.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. UNCY Dividend Analysis

5.1 Amount

  • No dividends for UNCY!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

UNCY Fundamentals: All Metrics, Ratios and Statistics

UNICYCIVE THERAPEUTICS INC

NASDAQ:UNCY (5/1/2026, 8:00:50 PM)

After market: 7.5597 -0.11 (-1.44%)

7.67

+0.01 (+0.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength54.04
Industry Growth13.66
Earnings (Last)03-30
Earnings (Next)05-19
Inst Owners33.82%
Inst Owner Change0%
Ins Owners2.49%
Ins Owner Change0%
Market Cap193.59M
Revenue(TTM)N/A
Net Income(TTM)-31.56M
Analysts82.86
Price Target42.11 (449.02%)
Short Float %8.78%
Short Ratio4.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)43.93%
Min EPS beat(2)31.11%
Max EPS beat(2)56.75%
EPS beat(4)3
Avg EPS beat(4)-6.92%
Min EPS beat(4)-183.22%
Max EPS beat(4)67.68%
EPS beat(8)4
Avg EPS beat(8)-40.65%
EPS beat(12)5
Avg EPS beat(12)-44.53%
EPS beat(16)6
Avg EPS beat(16)-39.36%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.21%
PT rev (3m)-11.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 11.78
P/tB 11.78
EV/EBITDA N/A
EPS(TTM)-2.17
EYN/A
EPS(NY)-1.35
Fwd EYN/A
FCF(TTM)-1.32
FCFYN/A
OCF(TTM)-1.31
OCFYN/A
SpS0
BVpS0.65
TBVpS0.65
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -105.21%
ROE -192.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-327.07%
ROA(5y)-432.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 251.85%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.18
Quick Ratio 2.18
Altman-Z 0.85
F-Score3
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)153.54%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.5%
EPS Next Y37.81%
EPS Next 2Y198.81%
EPS Next 3Y81.16%
EPS Next 5Y40.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.38%
EBIT Next 3Y175.15%
EBIT Next 5YN/A
FCF growth 1Y-73.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-73.69%
OCF growth 3YN/A
OCF growth 5YN/A

UNICYCIVE THERAPEUTICS INC / UNCY Fundamental Analysis FAQ

What is the fundamental rating for UNCY stock?

ChartMill assigns a fundamental rating of 2 / 10 to UNCY.


What is the valuation status for UNCY stock?

ChartMill assigns a valuation rating of 1 / 10 to UNICYCIVE THERAPEUTICS INC (UNCY). This can be considered as Overvalued.


Can you provide the profitability details for UNICYCIVE THERAPEUTICS INC?

UNICYCIVE THERAPEUTICS INC (UNCY) has a profitability rating of 0 / 10.


What is the earnings growth outlook for UNICYCIVE THERAPEUTICS INC?

The Earnings per Share (EPS) of UNICYCIVE THERAPEUTICS INC (UNCY) is expected to grow by 37.81% in the next year.


Can you provide the dividend sustainability for UNCY stock?

The dividend rating of UNICYCIVE THERAPEUTICS INC (UNCY) is 0 / 10 and the dividend payout ratio is 0%.